<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33971070</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1742-1241</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>75</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of clinical practice</Title>
          <ISOAbbreviation>Int J Clin Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder.</ArticleTitle>
        <Pagination>
          <StartPage>e14330</StartPage>
          <MedlinePgn>e14330</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e14330</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ijcp.14330</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">When clinicians evaluate potential medications for their patients, they must weigh the probability of a treatment's benefits against the possible risks. To this end, the present analyses evaluate the novel nonstimulant viloxazine extended-release (viloxazine ER) using measures of effect size to describe the potential benefits of its treatment in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) as well as the risk of discontinuation because of intolerable adverse events.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">These post hoc analyses use pooled data from four pivotal Phase 3 trials in paediatric patients treated with viloxazine ER. The Likelihood to be Helped or Harmed (LHH) effect size measure was calculated to describe the probability of patients benefiting from treatment vs discontinuing. The Number Needed to Treat (NNT) was calculated from frequently used thresholds of response. The Number Needed to Harm (NNH) was calculated using discontinuations because of adverse events.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">LHH values for viloxazine ER ranged from 5 to 13, suggesting that subjects were 5-13 times more likely to benefit from, rather than discontinue, viloxazine ER treatment. Specifically, NNT values for viloxazine ER treatment ranged from 6 to 7. NNH values for viloxazine ER treatment ranged from 31 to 74. By convention, single-digit NNTs (&lt;10) suggest the intervention is potentially useful, while NNH values ≥10 for adverse events suggest it is potentially safe or tolerable.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that patients with ADHD are likely to benefit from treatment with viloxazine ER, and are unlikely to discontinue, as viloxazine ER treatment was associated with favourable LHH, NNT, and NNH values. Clinicaltrials.gov: NCT03247530, NCT03247543, NCT03247517, NCT03247556.</AbstractText>
          <CopyrightInformation>© 2021 Supernus Pharmaceuticals Inc. International Journal of Clinical Practice published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kosheleff</LastName>
            <ForeName>Alisa R</ForeName>
            <Initials>AR</Initials>
            <Identifier Source="ORCID">0000-0002-5738-7221</Identifier>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hull</LastName>
            <ForeName>Joseph T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liranso</LastName>
            <ForeName>Tesfaye</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Peibing</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Busse</LastName>
            <ForeName>Gregory D</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fava</LastName>
            <ForeName>Maurizio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maletic</LastName>
            <ForeName>Vladimir</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, SC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rubin</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopez</LastName>
            <ForeName>Frank</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Developmental Center, Winter Park, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT03247517</AccessionNumber>
              <AccessionNumber>NCT03247543</AccessionNumber>
              <AccessionNumber>NCT03247556</AccessionNumber>
              <AccessionNumber>NCT03247530</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Clin Pract</MedlineTA>
        <NlmUniqueID>9712381</NlmUniqueID>
        <ISSNLinking>1368-5031</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="Y">Viloxazine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>A Nasser, AR Kosheleff, T Liranso, P Qin, JT Hull, GD Busse, and J Rubin are employees of Supernus Pharmaceuticals, Inc For a list of M Fava's lifetime disclosures, please see this link. V Maletic is an employee of the University of South Carolina School of Medicine. He is a consultant for ACADIA Pharmaceuticals Inc; Alfasigma USA, Inc; Alkermes, Inc; Allergan; Eisai‐Purdue; Intra‐Cellular Therapies; Janssen; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc; Sage Pharmaceuticals; Sunovion Pharmaceuticals Inc; Supernus Pharmaceuticals, Inc; and Takeda Pharmaceutical Company Limited. He serves on the speakers’ bureau of ACADIA Pharmaceuticals Inc; Alkermes, Inc; Allergan; Ironshore; Intra‐Cellular; Janssen; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc; Sunovion Pharmaceuticals Inc; and Takeda Pharmaceutical Company Limited; and his spouse serves on the speakers’ bureau of Otsuka America Pharmaceutical, Inc F Lopez has served as a consultant to and received speaker fees and/or research support from Eli Lilly, GSK, Ironshore, Neos, Novartis, Noven, Pfizer, Shire, Sunovion, Supernus, and Tris.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>18</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33971070</ArticleId>
        <ArticleId IdType="pmc">PMC8365735</ArticleId>
        <ArticleId IdType="doi">10.1111/ijcp.14330</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Singh A, Yeh CJ, Verma N, et al. Overview of attention deficit hyperactivity disorder in young children. Health Psychol Res. 2015;3:23‐35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4768532</ArticleId>
            <ArticleId IdType="pubmed">26973960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adesman AR. The diagnosis and management of attention‐deficit/hyperactivity disorder in pediatric patients. Prim Care Companion J Clin Psychiatry. 2001;3:66‐77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC181164</ArticleId>
            <ArticleId IdType="pubmed">15014618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danielson ML, Bitsko RH, Ghandour RM, et al. Prevalence of parent‐reported ADHD diagnosis and associated treatment Among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834391</ArticleId>
            <ArticleId IdType="pubmed">29363986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention‐deficit hyperactivity disorder: meta‐analysis. Br J Psychiatry. 2009;194:204‐211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19252145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessler RC, Adler LA, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163:716‐723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2859678</ArticleId>
            <ArticleId IdType="pubmed">16585449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polanczyk GV, de Lima MS, Horta BL, et al. The Worldwide Prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942‐948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17541055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turgay A, Goodman DW, Asherson P, et al. Lifespan persistence of ADHD: the life transition model and its application. J Clin Psychiatry. 2012;73:192‐201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22313720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T, Biederman J, Spencer T. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 2002;53:113‐131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11818466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese S. Pharmacologic treatment of attention deficit‐hyperactivity disorder. N Engl J Med. 2020;383:1050‐1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32905677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler LA, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Current Psychiatry Reports. 2006;8:409‐415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molife C, Bernauer MJ, Farr AM, et al. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. Postgrad Med. 2012;124:7‐22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23095422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T, Spencer T, Biederman J, et al. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 1995;34:110‐112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7860450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Concerta (Methylphenidate HCL) Extended Release [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652‐1658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7485630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65:38‐45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15046534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vyvanse (Lisdexamfetamine Dimesylate) [package insert]. Lexington, MA: Shire US Inc.; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Nafees B, Setyawan J, Lloyd A, et al. Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry. 2014;23:1189‐1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4246123</ArticleId>
            <ArticleId IdType="pubmed">24443092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamfetamine in children with attention defict hyperactivity disorder: a double‐blind, crossover trial. Pediatrics. 1997;100:662‐666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9310521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014;126:64‐81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25295651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemow DB. Misuse of methylphenidate. Curr Top Behav Neurosci. 2017;34:99‐124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26695166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21‐31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18174822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention‐deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:409‐432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8919704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. J Clin Psychiatry. 2010;71:754‐763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20051220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strattera (Atomoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, LLC; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Intuniv (Guanfacine Extended‐Release) [prescribing information]. Lexington, MA: Shire US Inc.; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28‐37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2880930</ArticleId>
            <ArticleId IdType="pubmed">20526405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kay SR. Positive‐negative symptom assessment in schizophrenia: psychometric issues and scale comparison. Psychiatr Q. 1990;61:163‐178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2075220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo‐controlled study of once‐daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:647‐655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15968233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. Sep‐Oct. 2005;22:498‐512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16418159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huss M, Sikirica V, Hervas A, et al. Guanfacine extended release for children and adolescents with attention‐deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment. Neuropsychiatr Dis Treat. 2016;112:1085‐1101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4863687</ArticleId>
            <ArticleId IdType="pubmed">27226715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stein MA, Sikirica V, Weiss MD, et al. Does guanfacine extended release impact functional impairment in children with attention‐deficit/hyperactivity disorder? Results from a randomized controlled trial. CNS Drugs. 2015;29:953‐962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4653245</ArticleId>
            <ArticleId IdType="pubmed">26547425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP‐104) in children with attention‐deficit/hyperactivity disorder: a phase III, multicenter, randomized, double‐blind, forced‐dose, parallel‐group study. Clin Ther. 2007;29:450‐463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17577466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011;72:1063‐1071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3457049</ArticleId>
            <ArticleId IdType="pubmed">21034695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia‐Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: Serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285‐300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3, randomized, placebo‐controlled trial to assess the efficacy and safety of once‐daily SPN‐812 (viloxazine extended release) in the treatment of ADHD in school‐age children. Clin Ther. 2020;42:1452‐1466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. Once‐daily SPN‐812 200 and 400 mg in the treatment of ADHD in school‐aged children: a phase III randomized, controlled trial. Clin Ther. 2021. [Epub ahead of print].</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A Phase 3, placebo‐controlled trial of once‐daily viloxazine extended‐release in adolescents with ADHD. J Clin Psychopharmacol. In press. [Epub ahead of print].</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8244935</ArticleId>
            <ArticleId IdType="pubmed">34181360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo‐controlled trial of once‐daily 400‐mg and 600‐mg SPN‐812 (Viloxazine Extended‐Release) in Adolescents with ADHD. Psychopharm Bul. 2021;51:43‐64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8146561</ArticleId>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Attention Disorders. 2001;5:107‐115.</Citation>
        </Reference>
        <Reference>
          <Citation>DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale‐5 for Children and Adolescents: Checklists, Norms, and Clinical Interpretation. Guilford Publications, 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Guy W. ECDEU assessment manual for psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs. 1976.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffman JIE. Odds Ratio, Relative Risk, Attributable Risk, and Number Needed to Treat. Biostatistics for Medical and Biomedical Practitioners, 2nd edn. Amsterdam, Netherlands: Elsevier Science; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67:407‐411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23574101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117:412‐419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18479317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309‐1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1114210</ArticleId>
            <ArticleId IdType="pubmed">9804726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michelson D, Allen AJ, Busner J, et al. Once‐daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo‐controlled study. Am J Psychiatry. 2002;159:1896‐1901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12411225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelsey D, Sumner CR, Casat CD, et al. Once‐daily atomoxetine treatment for children with attention‐deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double‐blind, placebo‐controlled trial. Pediatrics. 2004;113:e1‐e8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15231966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer T, Biederman J, Wilens T, et al. Efficacy of mixed amphetamine salts compound in adults with attention‐deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775‐782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11483144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28:1892‐1908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17213010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Kosheleff AR, Hull JT, et al. Translating attention‐deficit/hyperactivity disorder rating scale‐5 and weiss functional impairment rating scale‐parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN‐812 (Viloxazine Extended‐Release) in children and adolescents with attention‐deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021;31:214–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8066343</ArticleId>
            <ArticleId IdType="pubmed">33600233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman DW, Faraone SV, Adler LA, et al. Interpreting ADHD rating scale scores: linking ADHD rating scale scores and cgi levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry. 2010;17:44‐52.</Citation>
        </Reference>
        <Reference>
          <Citation>Citrome L. Can you interpret confidence intervals? It’s not that difficult. Curr Psychiatry. 2007;6:77‐82.</Citation>
        </Reference>
        <Reference>
          <Citation>Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001;22:102‐110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11306148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghirardi L, Larsson H, Chang Z, et al. Attention‐deficit/hyperactivity disorder medication and unintentional injuries in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2020;59:944‐951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6954332</ArticleId>
            <ArticleId IdType="pubmed">31302218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zetterqvist J, Asherson P, Halldner L, et al. Stimulant and non‐stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006–2009. Acta Psychiatr Scand. 2013;128:70‐77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22943458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy S, Asherson P, Coghill D, et al. Attention‐deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194:273‐277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19252159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong I, Asherson P, Bilbow A, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)‐pharmacoepidemiological and qualitative study. Health Technol Assess. 2009;13:1‐144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19883527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention‐deficit/hyperactivity disorder ‐ a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543‐1569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4149449</ArticleId>
            <ArticleId IdType="pubmed">25187718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller AR, Lalonde CE, McGrail KM. Children's persistence with methylphenidate therapy: a population‐based study. Can J Psychiatry. 2004;49:761‐768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15633854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta‐analysis. Eur Child Adolesc Psychiatry. 2010;19:353‐364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19763664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention‐deficit/hyperactivity disorder: results from a comprehensive meta‐analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53:174‐187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24472252</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33971070</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1742-1241</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>75</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of clinical practice</Title>
          <ISOAbbreviation>Int J Clin Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder.</ArticleTitle>
        <Pagination>
          <StartPage>e14330</StartPage>
          <MedlinePgn>e14330</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e14330</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ijcp.14330</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">When clinicians evaluate potential medications for their patients, they must weigh the probability of a treatment's benefits against the possible risks. To this end, the present analyses evaluate the novel nonstimulant viloxazine extended-release (viloxazine ER) using measures of effect size to describe the potential benefits of its treatment in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) as well as the risk of discontinuation because of intolerable adverse events.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">These post hoc analyses use pooled data from four pivotal Phase 3 trials in paediatric patients treated with viloxazine ER. The Likelihood to be Helped or Harmed (LHH) effect size measure was calculated to describe the probability of patients benefiting from treatment vs discontinuing. The Number Needed to Treat (NNT) was calculated from frequently used thresholds of response. The Number Needed to Harm (NNH) was calculated using discontinuations because of adverse events.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">LHH values for viloxazine ER ranged from 5 to 13, suggesting that subjects were 5-13 times more likely to benefit from, rather than discontinue, viloxazine ER treatment. Specifically, NNT values for viloxazine ER treatment ranged from 6 to 7. NNH values for viloxazine ER treatment ranged from 31 to 74. By convention, single-digit NNTs (&lt;10) suggest the intervention is potentially useful, while NNH values ≥10 for adverse events suggest it is potentially safe or tolerable.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that patients with ADHD are likely to benefit from treatment with viloxazine ER, and are unlikely to discontinue, as viloxazine ER treatment was associated with favourable LHH, NNT, and NNH values. Clinicaltrials.gov: NCT03247530, NCT03247543, NCT03247517, NCT03247556.</AbstractText>
          <CopyrightInformation>© 2021 Supernus Pharmaceuticals Inc. International Journal of Clinical Practice published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kosheleff</LastName>
            <ForeName>Alisa R</ForeName>
            <Initials>AR</Initials>
            <Identifier Source="ORCID">0000-0002-5738-7221</Identifier>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hull</LastName>
            <ForeName>Joseph T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liranso</LastName>
            <ForeName>Tesfaye</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Peibing</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Busse</LastName>
            <ForeName>Gregory D</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fava</LastName>
            <ForeName>Maurizio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maletic</LastName>
            <ForeName>Vladimir</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, SC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rubin</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopez</LastName>
            <ForeName>Frank</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Developmental Center, Winter Park, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT03247517</AccessionNumber>
              <AccessionNumber>NCT03247543</AccessionNumber>
              <AccessionNumber>NCT03247556</AccessionNumber>
              <AccessionNumber>NCT03247530</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Clin Pract</MedlineTA>
        <NlmUniqueID>9712381</NlmUniqueID>
        <ISSNLinking>1368-5031</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="Y">Viloxazine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>A Nasser, AR Kosheleff, T Liranso, P Qin, JT Hull, GD Busse, and J Rubin are employees of Supernus Pharmaceuticals, Inc For a list of M Fava's lifetime disclosures, please see this link. V Maletic is an employee of the University of South Carolina School of Medicine. He is a consultant for ACADIA Pharmaceuticals Inc; Alfasigma USA, Inc; Alkermes, Inc; Allergan; Eisai‐Purdue; Intra‐Cellular Therapies; Janssen; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc; Sage Pharmaceuticals; Sunovion Pharmaceuticals Inc; Supernus Pharmaceuticals, Inc; and Takeda Pharmaceutical Company Limited. He serves on the speakers’ bureau of ACADIA Pharmaceuticals Inc; Alkermes, Inc; Allergan; Ironshore; Intra‐Cellular; Janssen; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc; Sunovion Pharmaceuticals Inc; and Takeda Pharmaceutical Company Limited; and his spouse serves on the speakers’ bureau of Otsuka America Pharmaceutical, Inc F Lopez has served as a consultant to and received speaker fees and/or research support from Eli Lilly, GSK, Ironshore, Neos, Novartis, Noven, Pfizer, Shire, Sunovion, Supernus, and Tris.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>18</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33971070</ArticleId>
        <ArticleId IdType="pmc">PMC8365735</ArticleId>
        <ArticleId IdType="doi">10.1111/ijcp.14330</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Singh A, Yeh CJ, Verma N, et al. Overview of attention deficit hyperactivity disorder in young children. Health Psychol Res. 2015;3:23‐35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4768532</ArticleId>
            <ArticleId IdType="pubmed">26973960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adesman AR. The diagnosis and management of attention‐deficit/hyperactivity disorder in pediatric patients. Prim Care Companion J Clin Psychiatry. 2001;3:66‐77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC181164</ArticleId>
            <ArticleId IdType="pubmed">15014618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danielson ML, Bitsko RH, Ghandour RM, et al. Prevalence of parent‐reported ADHD diagnosis and associated treatment Among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834391</ArticleId>
            <ArticleId IdType="pubmed">29363986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention‐deficit hyperactivity disorder: meta‐analysis. Br J Psychiatry. 2009;194:204‐211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19252145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessler RC, Adler LA, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163:716‐723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2859678</ArticleId>
            <ArticleId IdType="pubmed">16585449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polanczyk GV, de Lima MS, Horta BL, et al. The Worldwide Prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942‐948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17541055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turgay A, Goodman DW, Asherson P, et al. Lifespan persistence of ADHD: the life transition model and its application. J Clin Psychiatry. 2012;73:192‐201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22313720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T, Biederman J, Spencer T. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 2002;53:113‐131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11818466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese S. Pharmacologic treatment of attention deficit‐hyperactivity disorder. N Engl J Med. 2020;383:1050‐1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32905677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler LA, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Current Psychiatry Reports. 2006;8:409‐415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molife C, Bernauer MJ, Farr AM, et al. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. Postgrad Med. 2012;124:7‐22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23095422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T, Spencer T, Biederman J, et al. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 1995;34:110‐112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7860450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Concerta (Methylphenidate HCL) Extended Release [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652‐1658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7485630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65:38‐45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15046534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vyvanse (Lisdexamfetamine Dimesylate) [package insert]. Lexington, MA: Shire US Inc.; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Nafees B, Setyawan J, Lloyd A, et al. Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry. 2014;23:1189‐1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4246123</ArticleId>
            <ArticleId IdType="pubmed">24443092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamfetamine in children with attention defict hyperactivity disorder: a double‐blind, crossover trial. Pediatrics. 1997;100:662‐666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9310521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014;126:64‐81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25295651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemow DB. Misuse of methylphenidate. Curr Top Behav Neurosci. 2017;34:99‐124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26695166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21‐31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18174822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention‐deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:409‐432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8919704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. J Clin Psychiatry. 2010;71:754‐763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20051220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strattera (Atomoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, LLC; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Intuniv (Guanfacine Extended‐Release) [prescribing information]. Lexington, MA: Shire US Inc.; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28‐37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2880930</ArticleId>
            <ArticleId IdType="pubmed">20526405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kay SR. Positive‐negative symptom assessment in schizophrenia: psychometric issues and scale comparison. Psychiatr Q. 1990;61:163‐178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2075220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo‐controlled study of once‐daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:647‐655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15968233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. Sep‐Oct. 2005;22:498‐512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16418159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huss M, Sikirica V, Hervas A, et al. Guanfacine extended release for children and adolescents with attention‐deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment. Neuropsychiatr Dis Treat. 2016;112:1085‐1101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4863687</ArticleId>
            <ArticleId IdType="pubmed">27226715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stein MA, Sikirica V, Weiss MD, et al. Does guanfacine extended release impact functional impairment in children with attention‐deficit/hyperactivity disorder? Results from a randomized controlled trial. CNS Drugs. 2015;29:953‐962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4653245</ArticleId>
            <ArticleId IdType="pubmed">26547425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP‐104) in children with attention‐deficit/hyperactivity disorder: a phase III, multicenter, randomized, double‐blind, forced‐dose, parallel‐group study. Clin Ther. 2007;29:450‐463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17577466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011;72:1063‐1071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3457049</ArticleId>
            <ArticleId IdType="pubmed">21034695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia‐Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: Serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285‐300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3, randomized, placebo‐controlled trial to assess the efficacy and safety of once‐daily SPN‐812 (viloxazine extended release) in the treatment of ADHD in school‐age children. Clin Ther. 2020;42:1452‐1466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. Once‐daily SPN‐812 200 and 400 mg in the treatment of ADHD in school‐aged children: a phase III randomized, controlled trial. Clin Ther. 2021. [Epub ahead of print].</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A Phase 3, placebo‐controlled trial of once‐daily viloxazine extended‐release in adolescents with ADHD. J Clin Psychopharmacol. In press. [Epub ahead of print].</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8244935</ArticleId>
            <ArticleId IdType="pubmed">34181360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo‐controlled trial of once‐daily 400‐mg and 600‐mg SPN‐812 (Viloxazine Extended‐Release) in Adolescents with ADHD. Psychopharm Bul. 2021;51:43‐64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8146561</ArticleId>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Attention Disorders. 2001;5:107‐115.</Citation>
        </Reference>
        <Reference>
          <Citation>DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale‐5 for Children and Adolescents: Checklists, Norms, and Clinical Interpretation. Guilford Publications, 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Guy W. ECDEU assessment manual for psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs. 1976.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffman JIE. Odds Ratio, Relative Risk, Attributable Risk, and Number Needed to Treat. Biostatistics for Medical and Biomedical Practitioners, 2nd edn. Amsterdam, Netherlands: Elsevier Science; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67:407‐411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23574101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117:412‐419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18479317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309‐1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1114210</ArticleId>
            <ArticleId IdType="pubmed">9804726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michelson D, Allen AJ, Busner J, et al. Once‐daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo‐controlled study. Am J Psychiatry. 2002;159:1896‐1901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12411225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelsey D, Sumner CR, Casat CD, et al. Once‐daily atomoxetine treatment for children with attention‐deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double‐blind, placebo‐controlled trial. Pediatrics. 2004;113:e1‐e8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15231966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer T, Biederman J, Wilens T, et al. Efficacy of mixed amphetamine salts compound in adults with attention‐deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775‐782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11483144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28:1892‐1908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17213010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Kosheleff AR, Hull JT, et al. Translating attention‐deficit/hyperactivity disorder rating scale‐5 and weiss functional impairment rating scale‐parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN‐812 (Viloxazine Extended‐Release) in children and adolescents with attention‐deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021;31:214–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8066343</ArticleId>
            <ArticleId IdType="pubmed">33600233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman DW, Faraone SV, Adler LA, et al. Interpreting ADHD rating scale scores: linking ADHD rating scale scores and cgi levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry. 2010;17:44‐52.</Citation>
        </Reference>
        <Reference>
          <Citation>Citrome L. Can you interpret confidence intervals? It’s not that difficult. Curr Psychiatry. 2007;6:77‐82.</Citation>
        </Reference>
        <Reference>
          <Citation>Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001;22:102‐110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11306148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghirardi L, Larsson H, Chang Z, et al. Attention‐deficit/hyperactivity disorder medication and unintentional injuries in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2020;59:944‐951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6954332</ArticleId>
            <ArticleId IdType="pubmed">31302218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zetterqvist J, Asherson P, Halldner L, et al. Stimulant and non‐stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006–2009. Acta Psychiatr Scand. 2013;128:70‐77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22943458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy S, Asherson P, Coghill D, et al. Attention‐deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194:273‐277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19252159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong I, Asherson P, Bilbow A, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)‐pharmacoepidemiological and qualitative study. Health Technol Assess. 2009;13:1‐144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19883527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention‐deficit/hyperactivity disorder ‐ a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543‐1569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4149449</ArticleId>
            <ArticleId IdType="pubmed">25187718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller AR, Lalonde CE, McGrail KM. Children's persistence with methylphenidate therapy: a population‐based study. Can J Psychiatry. 2004;49:761‐768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15633854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta‐analysis. Eur Child Adolesc Psychiatry. 2010;19:353‐364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19763664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention‐deficit/hyperactivity disorder: results from a comprehensive meta‐analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53:174‐187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24472252</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
